Lyn regulates creatine uptake in an imatinib-resistant CML cell line

BACKGROUND: Imatinib mesylate (imatinib) is the first-line treatment for newly diagnosed chronic myeloid leukemia (CML) due to its remarkable hematologic and cytogenetic responses. We previously demonstrated that the imatinib-resistant CML cells (Myl-R) contained elevated Lyn activity and intracellu...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Biochim Biophys Acta Gen Subj
Hlavní autoři: Okumu, Denis O., Aponte-Collazo, Lucas J., Dewar, Brian J., Cox, Nathan J., East, Michael P., Tech, Katherine, McDonald, Ian M., Tikunov, Andrey P., Holmuhamedov, Ekhson, Macdonald, Jeffrey M., Graves, Lee M.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7055176/
https://ncbi.nlm.nih.gov/pubmed/31881245
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbagen.2019.129507
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky